Tinkeso Therapeutics
Advancing NKT cell therapies for cancers and autoimmune disorders
- Headquarters
- Valhalla
- Employees
- 1–10
- Founded
- 2016
- Business Model
- B2B
- Website
- tinkeso.com
- Total Funding
- $600K
- Last Round
- $600K Venture RoundSep 2024
About
Tinkeso Therapeutics (formerly Akeso Therapeutics) is an early-stage biotechnology company based in Valhalla, New York, dedicated to advancing Natural Killer T (NKT) cell therapies for the treatment of cancers and autoimmune disorders. Founded in 2016, the company's pipeline covers both native and engineered NKT cell therapies. Its lead asset, IMK-101, is an engineered invariant NKT (iNKT) cell therapy targeting several types of leukemia. Operating from BioInc@NYMC in Valhalla, Tinkeso aims to address unmet patient needs with off-the-shelf, allogeneic cell therapy solutions.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account